Login
Please select your location and reference genome:
Congenica secures new two-year contract with Hong Kong Genome Project
News
genomics
HKGP

Congenica secures new two-year contract with Hong Kong Genome Project

10/4/2023    |    0 min read

 

 Congenica platform to continue providing tertiary analysis for Whole Genome Sequencing 

 

Cambridge, United Kingdom – 4 October 2023 - Congenica, a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale, today announces a two-year extension to their contract for the Hong Kong Genome Project (HKGP), the first large-scale genome sequencing initiative in Hong Kong.

 

The HKGP, implemented by the Hong Kong Genome Institute (HKGI) and funded by the HKSAR Government, serves as a catalyst for Hong Kong to establish a genome database of the local population, testing infrastructure and talent pool, all of which will facilitate clinical applications of genomic medicine and scientific research to benefit patients and their families, and the wider community in the long run.

 

Congenica was initially appointed for one year to provide tertiary analysis for Whole Genome Sequencing (WGS) based on its ability to support whole genome data analysis at scale. Since then, Congenica’s market-leading automation and Artificial Intelligence driven platform has enabled the identification of disease-causing variants in patients who are affected by undiagnosed diseases and hereditary cancer.

 

Alistair Johnson, Chief Professional Services Officer at Congenica, said: “We’re very pleased to be renewing our service contract for an extended two years with HKGI. This is testament not just to the performance of our platform in terms of efficiency and diagnostic yield, but also the customer support and services provided by our team on the ground to help deliver high quality results. We look forward to further strengthening our relationship with the team at HKGI and helping them to deliver precise diagnoses and more effective treatments to even more patients across Hong Kong.”